Table 4.
Angiogenesis-related factors according to chronic kidney disease stage
| Multivariable-adjusted median (IQR)a | p-value | |||
|---|---|---|---|---|
| Non-CKD controls (N = 201) |
CKD Stage 3 (N = 142) |
CKD Stage 4/5 (N = 59) |
||
| VEGF-A, pg/mL | 114.17 (72.45, 170.32) | 128.71 (89.19, 214.49) | 134.27 (95.73, 178.73) | 0.001 |
| Angiopoeitin-1, pg/mL | 4270.5 (2763.7, 6537.2) | 4026.3 (2511.6, 6881.9) | 3753.5 (2423.0, 6181.4) | 0.44 |
| Angiopoeitin-1/VEGF-A | 36.55 (25.71, 61.10) | 26.36 (18.82, 50.19) | 23.47 (16.83, 42.51) | 0.001 |
| VEGFR-1, ng/mL | 144.16 (123.74, 168.05) | 135.96 (118.60, 160.40) | 163.96 (135.19, 184.76) | 0.04 |
| VEGFR-2, ng/mL | 26.28 (23.10, 29.69) | 25.78 (22.23, 29.68) | 27.85 (23.12, 31.10) | 0.19 |
| Pentraxin-3, ng/mL | 0.89 (0.58, 1.18) | 1.01 (0.79, 1.38) | 1.04 (0.78, 1.58) | 0.06 |
aAdjusted for age, race, gender, current cigarette smoking, weekly alcohol consumption, physical activity ≥twice/week, BMI, LDL-cholesterol, HDL-cholesterol, C-reactive protein, fasting plasma glucose, systolic BP, use of aspirin or lipid-lowering, antihypertensive, or antidiabetic medications, and history of CVD